HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $4.5.
May 29, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Unicycive Therapeutics and maintained a price target of $4.5.
The reiteration of a Buy rating and the maintenance of a $4.5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100